| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
4 companies
Rajeev M. Shah last filed a Form 4 in May 2023, as Director, 10% Owner at SLDB. The filings on record cover 4 companies. Rajeev M. Shah's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 8,709,882 shares of SLDB. Net of sales, the SLDB filings show accumulation of 1,000,000 shares.
Rajeev M. Shah has 27 Form 4 filings on record from November 2016 to May 2023, across 4 companies: Director at Black Diamond Therapeutics (BDTX), 2020–2023; Director at Kala Bio (KALA), 2017–2021; Director, 10% Owner at Solid Biosciences (SLDB), 2018–2021, and 1 more.
The 36 reported transactions were 13 option or other derivative awards, 8 open-market purchases, 7 conversions and 6 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 6 purchases worth about $120.2M and no sales.
The largest open-market purchase was 6,337,135 shares of KALA at an average $7.89 on March 13, 2020, about $50.0M.
Shares as reported in the last Form 4 for each company; the most recent is from May 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2020 | KALA Kala Bio, Inc. | Director, 10% Owner | Buy | 6,337,135 | $7.89 | $49,999,995.15 | +139.7% | |
| Feb 3, 2020 | BDTX Black Diamond Therapeutics, Inc. | Director | Buy | 1,000,000 | $19.00 | $19,000,000.00 | -154.8% | |
| Oct 3, 2018 | KALA Kala Bio, Inc. | Director, 10% Owner | Buy | 2,424,242 | $8.25 | $19,999,996.50 | +114.7% | |
| Jan 30, 2018 | SLDB Solid Biosciences Inc. | Director | Buy | 1,000,000 | $16.00 | $16,000,000.00 | +59.2% | |
| Oct 12, 2017 | KALV Kalvista Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 850,000 | $8.50 | $7,225,000.00 | +143.8% | |
| Jul 25, 2017 | KALA Kala Bio, Inc. | Director | Buy | 533,333 | $15.00 | $7,999,995.00 | +33.8% |